Guardant Health Ordered to Pay $245M in Patent Infringement Case

Key Facts

In a move highlighting the escalating legal risks within the biotech sector, Guardant Health has been ordered by a court to pay over $245 million in damages. The finalized ruling stems from a patent infringement dispute involving Duplex Sequencing technology, which is owned by TwinStrand Biosciences and the University of Washington. According to reports, this decision concludes a significant legal battle over the intellectual property rights of this specific sequencing method.

The $245 million judgment represents a substantial financial burden for the company, likely impacting its cash reserves and future profit margins due to the requirement for ongoing royalties. Based on the analyst facts, the court found that Guardant Health infringed upon existing patents essential to genomic sequencing, thereby strengthening the competitive and legal standing of TwinStrand Biosciences in the industry.

With current market price levels for the instrument unavailable at this time, focus shifts to how the company will manage this major liability on its balance sheet. Traders should also monitor upcoming US economic catalysts, including Building Permits and Housing Starts data scheduled for August 18, 2026, for broader sentiment cues in the mid-cap equity space.